Aktieanalys

Xspray Pharma: CRL – FDA requiring additional information - Redeye

{newsItem.title}

Redeye Publicerad: 11 Jul 2023 10:14

Redeye expresses disappointment following this morning's news that Xspray has received a CRL for its NDA. We provide our comments and lower our base case as we await further information on how it will affect the timeline.

Länk till analysen i sin helhet: https://www.redeye.se/research/920897/xspray-pharma-crl-fda-requiring-additional-information?utm_source=finwire&utm_medium=RSS

Nyheter om Xspray Pharma

Läses av andra just nu

Om aktien Xspray Pharma

Senaste nytt